Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Don't Fear The Pricing Reaper

Executive Summary

The drug pricing debate has tarred many brushes in the pharmaceutical value chain. Whilst politicians may not yet be able to distinguish between the brazen price inflation of generic drugs and the high prices of innovative and recently launched branded drugs, the debate and rhetoric will eventually polarize. That polarization may be helped by new drugs with potentially very high list prices that are destined to be prescribed to very few patients.


Related Content

Teva Continues Divestitures To Close Allergan Deal With Sale To Impax


Related Companies